Evidence map›Paper›PMID 41358416›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

Rapid Bacteria Identification and Antimicrobial Susceptibility Testing via 5-Min Fluorescence In Situ Hybridization.

Lai Wei, Fangchi Shao, Sayuni Dharmasena, Sixuan Li, Jiyuan Yang, Arman Mirmiran, Pengfei Zhang, Shawna Lewis, Karen C Carroll, Kuangwen Hsieh and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lai WeiDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID https://orcid.org/0009-0007-9958-9239
Fangchi ShaoDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
Sayuni DharmasenaDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
Sixuan LiDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
Jiyuan YangDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
Arman MirmiranDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
Pengfei ZhangDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
Shawna LewisDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21218, USA.
Karen C CarrollDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21218, USA.
Kuangwen HsiehDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
Tza-Huei WangDepartment of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.ORCID https://orcid.org/0000-0002-3540-9354

Funding

Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections(AMR), and Emerging Infectious Diseases75N93024C00051 · NIAID · GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC · PI LENIGK, RALF · 2024 to 2024
$4.2M
Single-cell based diagnostic platform with single-molecular transcriptional response profiling for rapid phenotypic antimicrobial susceptibility testing of gonorrheaR01AI181217 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Tza-Huei Jeff Wang, SAMUEL YANG · 2024 to 2026
$2.3M
Integrated genotype-informed single-cell molecular antibacterial susceptibility testing platform for rapid and actionable diagnosis of bacteremiaR01AI183336 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Tza-Huei Jeff Wang · 2024 to 2026
$2.1M
NIAID NIH HHS 75N93024C00051NIAID NIH HHS R01 AI181217NIAID NIH HHS R01 AI183336NIH HHS 75N93024C00051NIH HHS R01AI181217NIH HHS RO1AI183336
6 · The paper itself

Abstract

Accurate and timely diagnosis of infections, including pathogen detection and antibiotic susceptibility testing (AST), is essential to effective disease management and combating antibiotic resistance. Here, SWIFT-FISH (Sensitive, Wash-free, Immediate, microFluidic, Thermal permeabilization-facilitated Fluorescence In Situ Hybridization), a novel diagnostic platform enabling bacterial identification (ID) in ≈5 min is reported, complemented by rapid AST. SWIFT-FISH significantly accelerates the conventional FISH workflow through transient thermal permeabilization, allowing intracellular hybridization of fluorescent peptide nucleic acid (PNA) probes to bacterial 16S ribosomal RNA (rRNA) without the conventional fixation step. SWIFT-FISH is then directly detected in solution within a continuous-flow microfluidic platform equipped with in-line single-cell resolution multi-color laser-induced fluorescence (LIF) detection. This approach boosts the cell-to-background ratio, which obviates the conventional washing step, while also enabling continuous cell delivery as a means for improving detection sensitivity. Using 3 broad-based probes and incorporating machine learning-based analysis, SWIFT-FISH demonstrates scalable identification of 6 bacterial species with ≈99% accuracy. Finally, by quantifying bacterial proliferation, SWIFT-FISH readily enables rapid phenotypic AST with ≈1 h turnaround time. SWIFT-FISH thus represents a simple, rapid, sensitive, and versatile diagnostic technology with significant potential to enhance clinical microbiology and antibiotic stewardship.

Indexed as

Anti-Bacterial AgentsBacteriaIn Situ Hybridization, FluorescenceMicrobial Sensitivity TestsRNA, Ribosomal, 16SAnti-Bacterial AgentsRNA, Ribosomal, 16Santimicrobial susceptibility testingbacteria identificationfluorescent in situ hybridizationlaser‐induced fluorescencemachine learning assisted diagnosisrapid diagnosis

Identifiers

PMID41358416
PMCPMC13045747

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.